Precision oncology: 2022 in review Review

  


Authors: Rosen, E.; Drilon, A.; Chakravarty, D.
Review Title: Precision oncology: 2022 in review
Abstract: This article presents a review of the major advances and future implications in precision oncology accomplished in 2022 and centers on three primary pillars: advances in (i) rational drug design, (ii) study design, and (iii) novel biomarkers. © 2022 American Association for Cancer Research.
Keywords: immunohistochemistry; protein expression; gene mutation; overall survival; somatic mutation; genetics; review; erlotinib; pancreas cancer; research design; methodology; neoplasm; neoplasms; tumor associated leukocyte; mass spectrometry; biological marker; dacarbazine; ipilimumab; cancer immunotherapy; melanoma; progression free survival; apoptosis; multiple myeloma; breast cancer; epidermal growth factor receptor 2; in vivo study; in vitro study; drug design; oncology; proteomics; tumor antigen; docetaxel; hyperglycemia; in situ hybridization; immunological tolerance; systematic review; carcinogenicity; tumor cell; medical oncology; chimeric antigen receptor; bile duct carcinoma; thyroid cancer; leiomyosarcoma; trastuzumab; uvea melanoma; tumor gene; thermostability; fibroblast growth factor receptor 2; pertuzumab; personalized medicine; non small cell lung cancer; langerhans cell histiocytosis; genotyping; phase 2 clinical trial (topic); phase 3 clinical trial (topic); phase 1 clinical trial (topic); acute myeloid leukemia; crizotinib; vemurafenib; trametinib; high throughput sequencing; nivolumab; humans; human; article; precision medicine; pembrolizumab; alectinib; alpelisib; durvalumab; brigatinib; lorlatinib; sotorasib
Journal Title: Cancer Discovery
Volume: 12
Issue: 12
ISSN: 2159-8274
Publisher: American Association for Cancer Research  
Date Published: 2022-12-01
Start Page: 2747
End Page: 2753
Language: English
DOI: 10.1158/2159-8290.Cd-22-1154
PUBMED: 36458431
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85143183803&doi=10.1158%2f2159-8290.CD-22-1154&partnerID=40&md5=e5fd4fe022568ec6caf44c2717a08618
Notes: Article -- Export Date: 3 January 2023 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Debyani Chakravarty
    87 Chakravarty
  2. Alexander Edward Drilon
    633 Drilon
  3. Ezra Y Rosen
    49 Rosen
Related MSK Work